Irakleia, a beautiful Greek island with just 148 residents, offers a serene escape with its untouched landscapes, charming ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating moderate-to ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Amorgos and Iraklia,’ she said. ‘These islands have fewer boat connections all year round, a couple of ferries per week, no airport, small communities, one doctor for the whole island and no ...

Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd ...

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment.